David J. Matlin Acquires 2,871,287 Shares of Clene Inc. (NASDAQ:CLNN) Stock
Clene Inc. (NASDAQ:CLNN – Get Rating) Director David J. Matlin purchased 2,871,287 shares of the company’s stock in a transaction on Wednesday, November 2nd. The shares were purchased at an average price of $1.01 per share, with a total value of $2,899,999.87. Following the completion of the purchase, the director now directly owns 5,293,684 shares of the company’s stock, valued at $5,346,620.84. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Clene Price Performance
Shares of NASDAQ CLNN opened at $1.11 on Friday. Clene Inc. has a fifty-two week low of $0.87 and a fifty-two week high of $6.12. The business has a 50 day moving average price of $2.19 and a two-hundred day moving average price of $2.74. The company has a quick ratio of 4.11, a current ratio of 4.13 and a debt-to-equity ratio of 9.64. The firm has a market cap of $70.49 million, a PE ratio of 5.29 and a beta of 0.15.
Clene (NASDAQ:CLNN – Get Rating) last issued its quarterly earnings data on Monday, August 15th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.01). Clene had a net margin of 4,138.77% and a negative return on equity of 819.50%. The business had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.07 million. Sell-side analysts expect that Clene Inc. will post -0.8 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of the company. Morgan Jess S & Co. Inc. lifted its holdings in Clene by 28.4% during the 3rd quarter. Morgan Jess S & Co. Inc. now owns 112,000 shares of the company’s stock worth $314,000 after buying an additional 24,750 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in Clene by 46.2% during the 2nd quarter. Goldman Sachs Group Inc. now owns 26,145 shares of the company’s stock worth $66,000 after buying an additional 8,262 shares during the last quarter. Jane Street Group LLC bought a new position in Clene during the 2nd quarter worth approximately $103,000. Cubist Systematic Strategies LLC bought a new position in Clene during the 2nd quarter worth approximately $29,000. Finally, Citadel Advisors LLC bought a new position in Clene during the 2nd quarter worth approximately $164,000. Institutional investors own 5.65% of the company’s stock.
Analysts Set New Price Targets
A number of research firms have recently issued reports on CLNN. Benchmark lowered their target price on Clene from $25.00 to $11.00 in a research note on Tuesday, October 4th. Oppenheimer lowered Clene from an “outperform” rating to a “market perform” rating in a research note on Tuesday, October 4th. HC Wainwright lowered their target price on Clene from $16.00 to $15.00 and set a “buy” rating for the company in a research note on Friday. Finally, Canaccord Genuity Group lowered their target price on Clene from $10.00 to $6.00 in a research note on Tuesday, October 4th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $11.80.
Clene Company Profile
Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain’s energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson’s Diseases.
Featured Articles
Receive News & Ratings for Clene Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Clene and related companies with MarketBeat.com’s FREE daily email newsletter.
